PuraStat becomes PuraBond for cardiac surgeons in Spain

In conjunction with its participation at the XXVI edition of the Secce’s congress in Oviedo, 3-D Matrix EMEA announced today, 16th June 2022 the launch of PuraBond for the cardiac surgery indications in the Spain market.

Following its constant growth and continuing the development of its pipeline, 3-D Matrix, already present in Spain with its haemostatic hydrogel “PuraStat” used to cover the gastrointestinal (GI) and cardiac medical specialities, announced the changeover of “PuraStat” to “PuraBond” for the cardiac surgery area.

PuraBond belongs to the self-assembling peptides family and is indicated for haemostasis. It comes in the form of a transparent gel in a prefilled syringe and, once in contact with bodily fluids such as blood, is able to achieve haemostasis by creating a three-dimensional barrier, similar to the human extracellular matrix, which stops the bleeding.

PuraBond is a ready to use agent in the market which does not swell after application, making it useful for a wide variety of surgical situations. With no preparation required, PuraBond in the cardiac area, is indicated in the following situations when haemostasis by ligation or standard means is insufficient or impractical: bleeding from small blood vessels and oozing from capillaries of the parenchyma and surrounding tissues of solid organs; oozing from vascular anastomoses to native or artificial vessels, on the surface of blood vessels and surrounding tissues[1].

The changeover process from “PuraStat” to “PuraBond” will be divided into phases and will become fully effective in Spain from August 2022.

To ensure the accessibility of PuraBond in Spain, 3-D Matrix will continue to collaborate and work closely with its distribution partner EpyCardio. Thanks to this collaboration, cardiac surgeons across the whole of Spain will have access to PuraBond as well as constant support and training for hospitals across the country.

This changeover process which has kickstarted in Spain represents part of a wider re-branding project for 3-D Matrix, which will also be rolled out across other European countries over the coming months.
With the final aim of facilitating and simplifying the routine and surgery practices, 3-D Matrix intends with this project to offer healthcare professionals a clearer breakdown of its product portfolio, with “PuraStat” focusing on the gastrointestinal and digestive area and “PuraBond” for the cardiac surgery area.


[1] PuraBond IFU-009_EN v2

Back to Blog